Login to Your Account



PHASE III TNBC TUNED IN, TOO

Looking out for Rindo: Stock sale garners Celldex $162M

By Randy Osborne
Staff Writer

Friday, December 6, 2013
Celldex Therapeutics Inc.’s public offering of 7 million shares at $24.50 each brings net proceeds of about $162.7 million, which should get the Hampton, N.J.-based firm “comfortably through 2016,” said CEO Anthony Marucci. “We came into the [financing] with $136.6 million already on the balance sheet,” he noted.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription